About CatalyScope

CatalyScope is a clinical intelligence publisher focused on Phase 3 development programs within small- and mid-cap pharmaceutical and biotechnology companies (market capitalisation below $10 billion USD). Our work centres on identifying and organising publicly disclosed primary endpoint readout timelines from ongoing clinical trials.

Clinical trial outcomes represent significant milestones in drug development. Primary endpoints are used by researchers and regulators to evaluate whether a therapy demonstrates sufficient efficacy and safety to justify further development. Understanding these programs requires synthesising information from clinical trial registries, sponsor disclosures, regulatory filings, and scientific literature.

CatalyScope uses automated data collection and AI-assisted summarisation through our Hidden Helix pipeline to systematically monitor public clinical trial databases. We present structured summaries of trial design, mechanisms of action, enrollment data, development history, condition context, and historical phase transition statistics to support research and analysis of clinical development activity.

In addition to our searchable database, CatalyScope publishes a detailed monthly report outlining the following month’s expected Phase 3 primary endpoint readouts within our coverage universe. The publication provides structured, research-oriented summaries intended to assist independent study of drug development timelines and industry activity.

CatalyScope does not provide investment advice, financial recommendations, or personalised guidance. We do not make predictions regarding commercial performance, share price movements, or clinical outcomes. All content is informational and educational in nature and is intended to support independent research and analysis within the life sciences sector.